Skip to main content
  • HF Benefit of Dapagliflozin Affirmed in Non-Diabetics

    Fewer CV events for heart failure with reduced ejection fraction

    PHILADELPHIA -- Heart failure patients with reduced ejection fraction but no diabetes appear to benefit significantly when the diabetes drug dapagliflozin (Farxiga) is added to their treatment regimens, researchers reported here.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details